Clinical Trials
Phase I Trial of CD19 CAR-T Cells With PD1/CD28 Switch Receptor in R/R B-Cell Lymphoma
Lin et alExperimental Hematology & Oncology

In a single-center, phase I clinical trial (ClinicalTrials.gov Identifier NCT03932955), adults with relapsed or refractory (R/R) B-cell lymphoma received autologous CD19 CAR-T cells incorporating a PD1/CD28 switch receptor. While CD19 CAR-T therapy achieves high remission rates in R/R B-cell lymphoma, efficacy is often limited by PD1/PD-L1–mediated immune suppression; the switch receptor was designed to convert inhibitory PD1 signals into CD28 costimulation to enhance efficacy.
The trial followed a 3 + 3 dose-escalation design with subsequent expansion cohorts. Primary endpoints were safety and feasibility, while secondary endpoints included efficacy, survival, CAR-T kinetics, and biomarker correlations. Thirty-two patients received CAR-T cells. During dose escalation, 6 of 9 patients responded, reflecting an overall response rate (ORR) of 66.7% and a complete response (CR) rate of 44.4%. Based on favorable responses at the highest dose (3 × 10^6/kg), 23 additional patients were treated in cohort expansion, yielding an ORR of 87.0% and a CR rate of 69.6%.
At a median follow-up of 34 months, median duration of response (DOR) and overall survival (OS) were not reached. The 12- and 36-month DOR rates were 58.6% and 53.3%, respectively. Median progression-free survival (PFS) was 12 months, with a 3-year PFS rate of 43.3%. Overall survival reached 82% at 1 year and 64% at 3 years. Responses occurred across baseline PD-L1 strata, and no significant association was detected between baseline PD-L1 expression and response.
Regarding safety, cytokine release syndrome occurred in 62.5% of patients (all grade 1–2) and neurotoxicity occurred in 6.3% (grade 2–3). The authors concluded that CD19&PD1/CD28 CAR-T therapy achieved high response rates, durable remissions, and manageable toxicity in R/R B-cell lymphoma, although the single-arm design precludes attribution of efficacy to the switch receptor.
Key Takeaways
- In the cohort expansion at the highest dose of 3 × 10^6/kg (n=23), autologous CD19 CAR-T cells incorporating a PD1/CD28 switch receptor achieved an overall response rate of 87.0% and a complete response rate of 69.6%, compared with 66.7% and 44.4%, respectively, in dose escalation (n=9).
- At a median follow-up of 34 months, median duration of response and overall survival were not reached, with 12- and 36-month duration of response rates of 58.6% and 53.3%, a 3-year progression-free survival of 43.3%, and a 3-year overall survival of 64%.
- Cytokine release syndrome occurred in 62.5% of patients (all grade 1–2) and neurotoxicity occurred in 6.3% (grade 2–3), with no significant association detected between baseline PD-L1 expression and clinical response.
Read the original sourceExperimental Hematology & Oncology
